Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

72 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Adenosine receptors and cancer.
Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Gessi S, et al. Among authors: simioni c. Biochim Biophys Acta. 2011 May;1808(5):1400-12. doi: 10.1016/j.bbamem.2010.09.020. Epub 2010 Oct 1. Biochim Biophys Acta. 2011. PMID: 20888788 Review.
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, Borea PA. Merighi S, et al. Among authors: simioni c. Mol Pharmacol. 2007 Aug;72(2):395-406. doi: 10.1124/mol.106.032920. Epub 2007 May 8. Mol Pharmacol. 2007. PMID: 17488804
Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors.
Merighi S, Simioni C, Gessi S, Varani K, Borea PA. Merighi S, et al. Among authors: simioni c. Biochem Pharmacol. 2010 Feb 1;79(3):471-7. doi: 10.1016/j.bcp.2009.09.009. Epub 2009 Sep 18. Biochem Pharmacol. 2010. PMID: 19766600
Affinity constants were measured on CHO cells transfected with the human CB(1) and CB(2) receptors by inhibition assays of the binding of the cannabinoid receptor agonist [(3)H]-CP-55,940. van't Hoff plots were linear for agonists and antagonists in the temperature range 0-30 deg …
Affinity constants were measured on CHO cells transfected with the human CB(1) and CB(2) receptors by inhibition assays of the binding of th …
A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin.
Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, Baraldi PG, Borea PA. Merighi S, et al. Among authors: simioni c. Neoplasia. 2009 Oct;11(10):1064-73. doi: 10.1593/neo.09768. Neoplasia. 2009. PMID: 19794965 Free PMC article.
Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.
Merighi S, Gessi S, Varani K, Simioni C, Fazzi D, Mirandola P, Borea PA. Merighi S, et al. Among authors: simioni c. Br J Pharmacol. 2012 Mar;165(6):1773-1788. doi: 10.1111/j.1476-5381.2011.01673.x. Br J Pharmacol. 2012. PMID: 21951063 Free PMC article. Retracted.
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy.
Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. Simioni C, et al. Oncotarget. 2013 Sep;4(9):1496-506. doi: 10.18632/oncotarget.1236. Oncotarget. 2013. PMID: 24036604 Free PMC article.
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM. Simioni C, et al. Leukemia. 2012 Nov;26(11):2336-42. doi: 10.1038/leu.2012.136. Epub 2012 May 22. Leukemia. 2012. PMID: 22614243
Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA, Capitani S. Neri LM, et al. Among authors: simioni c. Leukemia. 2014 Apr;28(4):739-48. doi: 10.1038/leu.2013.226. Epub 2013 Jul 29. Leukemia. 2014. PMID: 23892718
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM. Simioni C, et al. Oncotarget. 2014 Oct 30;5(20):10034-47. doi: 10.18632/oncotarget.2490. Oncotarget. 2014. PMID: 25296981 Free PMC article.
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Cani A, et al. Among authors: simioni c. Oncotarget. 2015 Mar 30;6(9):6597-610. doi: 10.18632/oncotarget.3260. Oncotarget. 2015. PMID: 25788264 Free PMC article.
72 results
Jump to page
Feedback